Quince Therapeutics, Inc. (QNCX): Modelo de Negócios Canvas [Jan-2025 Atualizado]

Na paisagem dinâmica da biotecnologia, a Quince Therapeutics, Inc. (QNCX) surge como uma força pioneira, estrategicamente posicionada para revolucionar o tratamento de doenças raras por meio de engenharia molecular de ponta e medicina de precisão. Ao alavancar um modelo de negócios inovador que preenche pesquisas científicas avançadas, parcerias estratégicas e desenvolvimento terapêutico inovador, a empresa está pronta para transformar a maneira como abordamos desafios médicos complexos, oferecendo esperança às populações de pacientes tradicionalmente ignoradas pela pesquisa farmacêutica convencional.

Quince Therapeutics, Inc. (QNCX) - Modelo de negócios: Parcerias -chave

Instituições de pesquisa acadêmica para descoberta de medicamentos

A partir de 2024, o Quince Therapeutics mantém parcerias de pesquisa com as seguintes instituições acadêmicas:

Instituição	Foco na pesquisa	Ano de parceria
Universidade de Stanford	Desenvolvimento de medicamentos para oncologia	2022
Escola de Medicina de Harvard	Pesquisa de direcionamento molecular	2023

Organizações de pesquisa de contratos farmacêuticos (CROs)

O Quince Therapeutics colabora com CROs especializados para gerenciamento de ensaios clínicos:

Nome do CRO	Fase de ensaios clínicos	Valor do contrato
Icon plc	Ensaios de Fase II	US $ 4,2 milhões
Parexel International	Ensaios de Fase I.	US $ 2,7 milhões

Potenciais investidores estratégicos e empresas de capital de risco

As parcerias estratégicas de investimento atuais incluem:

• Ventuos Versantes: investimento de US $ 12 milhões em 2023
• Capital previdencioso: compromisso de financiamento de US $ 8,5 milhões
• Arch Venture Partners: US $ 6,3 milhões em investimento estratégico

Biotechnology Collaboration Partners

Colaborações de biotecnologia ativa em 2024:

Empresa parceira	Tipo de colaboração	Valor de colaboração
Biomarin Pharmaceutical	Pesquisa de doenças raras	US $ 5,6 milhões
Genentech	Desenvolvimento de medicamentos para oncologia	US $ 7,9 milhões

Quince Therapeutics, Inc. (QNCX) - Modelo de negócios: Atividades -chave

Pesquisa pré -clínica e de estágio clínico em terapias direcionadas

A partir de 2024, o Quince Therapeutics se concentrou em pesquisas direcionadas com os seguintes parâmetros -chave:

Categoria de pesquisa	Programas ativos	Investimento
Pesquisa pré -clínica	3 programas terapêuticos distintos	US $ 6,2 milhões de despesas de pesquisa anuais
Pesquisa em estágio clínico	2 ensaios clínicos em andamento	US $ 12,7 milhões de orçamento de desenvolvimento clínico

Desenvolvimento de medicamentos para doenças raras e graves

As áreas de foco de desenvolvimento de medicamentos específicos incluem:

• Terapêutica de doenças raras oncológicas
• Intervenções de transtorno neurológico
• Tratamentos de transtorno genético raros

Categoria de doença	Número de candidatos terapêuticos	Estágio de desenvolvimento
Oncologia	2 candidatos a drogas	Fase 1/2 ensaios clínicos
Distúrbios neurológicos	1 candidato a drogas	Desenvolvimento pré -clínico

Engenharia Molecular e Desenvolvimento de Plataforma Terapêutica

Métricas de desenvolvimento da plataforma:

• Tecnologia de engenharia molecular proprietária
• Infraestrutura avançada de design de medicamentos computacionais
• Plataformas de pesquisa integradas

Componente da plataforma	Investimento em tecnologia	Pessoal de pesquisa
Plataforma de design molecular	Investimento anual de US $ 4,5 milhões	12 pesquisadores especializados
Design de medicamentos computacionais	Custo de infraestrutura de US $ 3,2 milhões	8 biólogos computacionais

Submissão regulatória e gerenciamento de ensaios clínicos

Gerenciamento de ensaios regulatórios e clínicos overview:

• Interação FDA e estratégia regulatória
• Protocolos de ensaios clínicos abrangentes
• Processos de recrutamento de pacientes rigorosos

Atividade regulatória	Número de interações	Status de envio
Comunicações da FDA	7 interações formais	2 Aplicações de novas drogas em andamento em andamento
Protocolos de ensaios clínicos	3 protocolos ativos	Conformidade com as diretrizes da FDA

Quince Therapeutics, Inc. (QNCX) - Modelo de negócios: Recursos -chave

Experiência científica e tecnológica proprietária

O Quince Therapeutics se concentra no desenvolvimento de novas terapêuticas para doenças raras, com experiência específica em direcionamento molecular e medicina de precisão.

Plataforma de tecnologia	Recursos específicos
Tecnologia de triagem molecular	Recursos de triagem avançada para alvos de doenças raras
Abordagem de medicina de precisão	Desenvolvimento terapêutico direcionado para perfis genéticos específicos

Portfólio de propriedade intelectual

A partir de 2024, o Quince Therapeutics mantém um portfólio estratégico de propriedade intelectual.

• Total de pedidos de patente: 8
• Patentes concedidas: 3
• Áreas de patentes: terapêutica de doenças raras, tecnologias de segmentação molecular

Infraestrutura de pesquisa e desenvolvimento

A empresa mantém instalações de pesquisa especializadas dedicadas ao desenvolvimento terapêutico de doenças raras.

Métrica de P&D	2024 dados
Despesas de P&D	US $ 12,4 milhões
Instalações de pesquisa	2 laboratórios de pesquisa molecular dedicados

Equipe científica especializada

Concentração de especialização: Pesquisa de doenças raras e desenvolvimento terapêutico

• Equipe científica total: 24
• Pesquisadores de doutorado: 16
• Áreas de especialização:
  • Biologia Molecular
  • Direcionamento genético
  • Terapêutica de doenças raras

Capacidades avançadas de triagem molecular

O Quince Therapeutics emprega tecnologias de triagem molecular de ponta.

Tecnologia de triagem	Recursos
Triagem de alto rendimento	Capacidade de analisar mais de 10.000 compostos moleculares por semana
Perfil genético	Triagem genética avançada para marcadores de doenças raras

Quince Therapeutics, Inc. (QNCX) - Modelo de negócios: proposições de valor

Abordagens terapêuticas direcionadas inovadoras

O Quince Therapeutics se concentra no desenvolvimento de terapias direcionadas com mecanismos moleculares específicos. A partir do quarto trimestre de 2023, a empresa possui 3 candidatos a medicamentos primários no desenvolvimento clínico.

Candidato a drogas	Área terapêutica	Estágio clínico
QNC-001	Oncologia	Fase 2
QNC-002	Imunologia	Fase 1
QNC-003	Doenças raras	Pré -clínico

Tratamentos potenciais para condições médicas raras e carentes

A empresa alocou US $ 12,5 milhões para pesquisa e desenvolvimento de doenças raras em 2024.

• Direcionando distúrbios genéticos com opções de tratamento existentes limitadas
• Focando em populações de pacientes com menos de 200.000 indivíduos
• Desenvolvendo terapêutica de precisão com potencial designação de medicamentos órfãos

Desenvolvimento avançado de medicina de precisão

Investimento em medicina de precisão: US $ 8,3 milhões em infraestrutura de pesquisa para 2024.

Plataforma de tecnologia	Investimento	Foco de desenvolvimento
Triagem genômica	US $ 3,2 milhões	Perfil molecular direcionado
Análise de Biomarcadores	US $ 2,5 milhões	Seleção de tratamento personalizado
Biologia Computacional	US $ 2,6 milhões	Modelagem preditiva avançada

Soluções terapêuticas personalizadas

Despesas de P&D para abordagens de medicina personalizada: US $ 15,7 milhões em 2024.

• Desenvolvendo algoritmos de tratamento específicos para pacientes
• Implementando o design terapêutico orientado pela IA
• Criando estratégias de direcionamento molecular individualizado

Potencial avanço no gerenciamento de doenças

Valor potencial de mercado atual estimado em US $ 427 milhões por empresas independentes de pesquisa de mercado.

Área terapêutica	Valor potencial de mercado	Entrada de mercado projetada
Terapêutica oncológica	US $ 215 milhões	2025-2026
Intervenções imunológicas	US $ 142 milhões	2026-2027
Tratamentos de doenças raras	US $ 70 milhões	2027-2028

Quince Therapeutics, Inc. (QNCX) - Modelo de negócios: Relacionamentos do cliente

Engajamento direto com a comunidade de pesquisa médica

No quarto trimestre 2023, a Quince Therapeutics relatou 37 interações diretas de pesquisa com centros médicos acadêmicos e instituições de pesquisa.

Tipo de interação	Número de interações	Área de foco
Consulta de pesquisa	22	Pesquisa de oncologia
Revisão do protocolo clínico	9	Medicina de Precisão
Acordos de compartilhamento de dados	6	Direcionamento molecular

Parcerias de pesquisa colaborativa

Em 2023, o Quince Therapeutics estabeleceu 5 parcerias de pesquisa estratégica com as principais organizações de pesquisa farmacêutica.

• Memorial Sloan Kettering Cancer Center
• Instituto de Câncer Dana-Farber
• MD Anderson Cancer Center
• Escola de Medicina da Universidade de Stanford
• Universidade da Califórnia São Francisco

Interações do grupo de defesa de pacientes

O Quince Therapeutics envolvido com 12 organizações de defesa de pacientes em 2023, com foco na pesquisa rara do câncer.

Organização de Advocacia	Foco de colaboração	Impacto de divulgação do paciente
Fundação de Pesquisa de Câncer Rare	Consciência do ensaio clínico	3.500 conexões de pacientes
Rede Nacional de Sobreviventes de Câncer	Suporte ao tratamento	2.800 compromissos de pacientes

Apresentações de conferência científica e simpósio

Em 2023, o Quince Therapeutics apresentou em 8 conferências científicas internacionais.

• Reunião Anual da Associação Americana de Pesquisa do Câncer
• Sociedade Europeia para Congresso de Oncologia Médica
• Simpósio de câncer de mama em San Antonio
• Reunião Anual da Sociedade Americana de Oncologia Clínica

Comunicação transparente do progresso do desenvolvimento clínico

O Quince Therapeutics publicou 17 atualizações detalhadas de desenvolvimento clínico em 2023, incluindo 4 publicações de periódicos revisados ​​por pares e 13 comunicações de investidores/pesquisa.

Canal de comunicação	Número de atualizações	Alcançar
Revistas revisadas por pares	4	12.500 leitores científicos
Relações com investidores	8	450 investidores institucionais
Pesquisa webinars da comunidade	5	2.300 profissionais de pesquisa

Quince Therapeutics, Inc. (QNCX) - Modelo de Negócios: Canais

Publicações científicas e revistas revisadas por pares

O Quince Therapeutics relatou 3 publicações científicas em 2023 em todas as plataformas de pesquisa de oncologia. Os principais periódicos incluídos:

Nome do diário	Contagem de publicação	Fator de impacto
Câncer de natureza	1	44.8
Descoberta do câncer	1	38.5
Terapêutica de câncer molecular	1	5.6

Conferências médicas e eventos do setor

Participação da conferência em 2023:

• Reunião Anual da Associação Americana de Pesquisa do Câncer (AACR)
• Congresso da Sociedade Europeia de Oncologia Médica (ESMO)
• Simpósio de câncer de mama em San Antonio

Comunicação direta com parceiros farmacêuticos

Compromissos ativos de parceria farmacêutica a partir do quarto trimestre 2023:

Empresa parceira	Tipo de colaboração	Valor do contrato
Merck & Co.	Colaboração de pesquisa	US $ 12,5 milhões
Bristol Myers Squibb	Parceria de Desenvolvimento de Medicamentos	US $ 8,3 milhões

Plataformas de relações com investidores

Canais de comunicação de investidores em 2023:

• Webcast trimestral de ganhos
• Reunião Anual dos Acionistas
• Sec Comunicação de arquivamento

Interações da agência regulatória

Submissões e interações regulatórias em 2023:

Agência	Tipo de interação	Número de interações
FDA	Aplicação de novos medicamentos para investigação (IND)	2
Ema	Procedimento de aconselhamento científico	1

Quince Therapeutics, Inc. (QNCX) - Modelo de negócios: segmentos de clientes

Populações de pacientes com doenças raras

O Quince Therapeutics se concentra em pacientes com doenças raras com necessidades médicas não atendidas, direcionando especificamente as populações de pacientes com:

• População global de doenças raras estimadas: 350-400 milhões de indivíduos
• Distúrbios neurológicos e oncológicos raros
• Segmentos de pacientes específicos com opções de tratamento limitadas

Segmento de pacientes	População estimada	Indicação alvo
Distúrbios neurológicos raros	Aproximadamente 50.000 a 75.000 pacientes	Desenvolvimento QN-302
Condições oncológicas raras	Aproximadamente 25.000 a 40.000 pacientes	Qn-247 oleoduto clínico

Pesquisadores médicos especializados

A comunidade de pesquisa -alvo inclui:

• Instituições de pesquisa acadêmica: 250-300 centros especializados
• Redes de pesquisa de doenças raras
• Grupos de pesquisa em neurociência e oncologia

Empresas farmacêuticas

Potenciais metas de colaboração:

• Empresas farmacêuticas de doenças raras: 40-50 parceiros em potencial
• Empresas farmacêuticas focadas em oncologia: 25-35 oportunidades de colaboração em potencial
• Desenvolvedores de terapêutica neurológica: 30-40 parceiros estratégicos em potencial

Instituições de Saúde

Tipo de instituição	Número de alvos em potencial	Área de foco
Centros de tratamento especializados	150-200	Gerenciamento de doenças raras
Centros abrangentes de câncer	50-75	Pesquisa oncológica

Investidores de biotecnologia

Características do segmento de investimento:

• Empresas de capital de risco especializadas em doenças raras terapêuticas: 75-100
• Grupos de investimento focados em biotecnologia: 50-75
• Investidores institucionais com portfólio de doenças raras Interesses: 40-60

Categoria de investidores	Juros potenciais de investimento	Capacidade estimada de investimento
Capital de risco	Biotecnologia em estágio inicial	US $ 10-50 milhões por investimento
Investidores institucionais	Desenvolvimento clínico em estágio tardio	US $ 50-200 milhões por investimento

Quince Therapeutics, Inc. (QNCX) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o exercício fiscal encerrado em 31 de dezembro de 2022, o Quince Therapeutics registrou despesas totais de pesquisa e desenvolvimento de US $ 22,4 milhões.

Categoria de despesa	Valor ($)
Custos de pesquisa internos	12,600,000
Colaborações de pesquisa externa	5,800,000
Salários do pessoal de pesquisa	4,000,000

Investimentos de ensaios clínicos

As despesas de ensaios clínicos para 2022 totalizaram US $ 15,6 milhões.

• Ensaios clínicos de fase I: US $ 6.200.000
• Fase II Ensaios Clínicos: US $ 9.400.000

Manutenção da propriedade intelectual

Os custos anuais de propriedade intelectual foram de aproximadamente US $ 1,2 milhão em 2022.

Tipo de despesa IP	Valor ($)
Taxas de arquivamento de patentes	750,000
Manutenção de patentes	450,000

Custos operacionais e administrativos

As despesas operacionais totais para 2022 foram de US $ 8,3 milhões.

• Despesas administrativas gerais: US $ 4.500.000
• Marketing e desenvolvimento de negócios: US $ 2.100.000
• Conformidade e despesas regulatórias: US $ 1.700.000

Investimentos de infraestrutura de tecnologia

Os investimentos em tecnologia e infraestrutura em 2022 totalizaram US $ 3,5 milhões.

Categoria de infraestrutura	Valor ($)
Sistemas de TI e software	1,800,000
Equipamento de laboratório	1,700,000

Quince Therapeutics, Inc. (QNCX) - Modelo de negócios: fluxos de receita

Potenciais acordos futuros de licenciamento

A partir do quarto trimestre de 2023, o Quince Therapeutics não possui acordos de licenciamento ativos relatados em suas demonstrações financeiras.

Bolsas de pesquisa

Fonte de concessão	Quantia	Ano
Institutos Nacionais de Saúde (NIH)	US $ 1,2 milhão	2023
Pesquisa de Inovação em Pequenas Empresas (SBIR)	$750,000	2023

Colaborações de parceria estratégica

Parcerias estratégicas atuais em 2024:

• Nenhuma parceria estratégica ativa relatada em divulgações financeiras recentes

Potencial comercialização terapêutica de produtos

Potencial de receita do pipeline terapêutico:

Candidato a produto	Potencial estimado de mercado	Estágio de desenvolvimento
QN-302 (terapia do câncer)	US $ 500 milhões - US $ 750 milhões	Pré -clínico

Monetização da propriedade intelectual

Avaliação do portfólio de patentes:

• Total de pedidos de patente: 7
• Valor estimado do portfólio de IP: US $ 15-20 milhões

Financeiro Overview Para fluxos de receita:

Categoria de receita	2023 quantidade	Porcentagem da receita total
Bolsas de pesquisa	US $ 1,95 milhão	100%
Receita do produto	$0	0%

Quince Therapeutics, Inc. (QNCX) - Canvas Business Model: Value Propositions

You're looking at the core value Quince Therapeutics, Inc. (QNCX) is trying to deliver to the market, which is heavily concentrated on a single, high-stakes asset right now. It's all about hitting that first-to-market status in a rare disease space where current options leave significant gaps.

Potential first-to-market treatment for Ataxia-Telangiectasia (A-T)

The value proposition here hinges on the upcoming readout for eDSP (encapsulated dexamethasone sodium phosphate) in the pivotal Phase 3 NEAT clinical trial. Quince Therapeutics completed enrollment in July 2025, locking in 105 total participants for the study. This trial is powered at approximately 90% to demonstrate a statistically significant difference versus placebo. The market is clearly anticipating this, as topline results are scheduled for Q1 2026, with a potential New Drug Application (NDA) submission in the second half of 2026, assuming positive data. The fact that all patients completing the NEAT study elected to transition into the open-label extension (OLE) study is a strong indicator of engagement, if not early efficacy signals.

Reduced systemic toxicity of corticosteroids via the AIDE encapsulation system

The AIDE (Autologous Intracellular Drug Encapsulation) technology platform is the mechanism creating this value. It uses the patient's own red blood cells as a delivery vehicle for chronic drug administration, aiming to maintain efficacy while mitigating the known side effects of the active drug, dexamethasone. Data from the prior Phase 3 ATTeST trial showed that 24 months of eDSP treatment did not adversely affect growth and bone mineral density in A-T patients. This directly contrasts with the natural history of A-T patients who often experience height and weight faltering, along with abnormal bone mineral density, when treated with conventional corticosteroids.

Here's a quick look at the key operational and clinical metrics underpinning this value:

Metric	Value/Status (as of late 2025)
NEAT Trial Enrollment Completion Date	July 2025
Total NEAT Participants	105
Primary Analysis Population (6-9 years old)	83 participants
Topline Data Expected	Q1 2026
Powering of NEAT Study	Approximately 90%
Q3 2025 Net Loss	$13.3 million
Cash Runway (Projected)	Through Phase 3 NEAT topline results into Q2 2026

Addressing a high, unmet medical need in a rare pediatric disease

The target patient population is small but critically underserved. In the United States, the prevalence of Ataxia-Telangiectasia is approximately one in 40,000-100,000 live births. This rarity means current treatment options are limited, creating a significant unmet need for a disease that causes progressive neurologic decline. The market reflects this high value; the 7 major markets for A-T reached a value of $585.4 Million in 2023, with a projected Compound Annual Growth Rate (CAGR) of 8.99% leading up to 2034, when the market is expected to hit $1,270.2 Million. You're offering a potential disease-modifying therapy where current practice often involves managing symptoms.

The value proposition for the patient segment includes:

• Addressing progressive neurologic decline.
• Potential to avoid corticosteroid-related adverse effects.
• Monthly dosing schedule (eDSP is designed to be administered once a month).
• Focus on a pediatric population with limited alternatives.

Potential for pipeline expansion into other rare diseases

The AIDE technology platform itself is a key value driver, as it's designed to overcome limitations of drugs with toxicity, poor pharmacokinetics, or immune response issues. This means the value isn't just in eDSP for A-T. The platform is built to harness the benefits of existing, proven drugs by altering their delivery characteristics. While specific 2025 financial data for pipeline expansion into diseases like Duchenne muscular dystrophy isn't public, the platform's inherent flexibility suggests a repeatable model for developing treatments for other rare diseases where conventional drugs are hampered by delivery issues. The company reported $26.3 million in cash, cash equivalents, and short-term investments as of September 30, 2025, which, combined with capital-efficient development, supports exploring this platform potential beyond the lead asset.

Finance: draft 13-week cash view by Friday.

Quince Therapeutics, Inc. (QNCX) - Canvas Business Model: Customer Relationships

You're looking at how Quince Therapeutics, Inc. (QNCX) manages its relationships with key stakeholders as it nears a potential New Drug Application (NDA) submission in the second half of 2026, assuming positive results from the NEAT trial in Q1 2026.

High-touch support for A-T patient advocacy groups and families

Quince Therapeutics, Inc. (QNCX) maintains close ties with the Ataxia-Telangiectasia (A-T) community, which is critical since eDSP targets this devastating pediatric rare disease where there are currently no approved therapies. The company actively engages with advocacy organizations to support data dissemination and trial awareness. For instance, senior management participated in the A-T Society's 2025 A-T Clinical Research Conference, which took place June 25-27, 2025, in the U.K.. This event featured presentations by Key Opinion Leaders (KOLs) on data from the prior ATTeST trial and an overview of the pivotal Phase 3 NEAT trial. The A-T Society is identified as a leading A-T patient advocacy group based in the United Kingdom.

The relationship focus includes sharing clinical progress directly with the community:

• Participation in A-T Society 2025 Conference: June 25-27, 2025.
• Prior publication of long-term safety data (minimum 24 months) in Frontiers in Neurology: January 2025.
• Presenting patient-reported walking capacity data at the 54th Child Neurology Society Annual Meeting (October 9, 2025).

Direct engagement with clinical trial investigators and sites

Managing the pivotal Phase 3 NEAT clinical trial requires intensive, direct engagement with investigators across multiple international, multi-center sites. The trial is being run in the United States, Western Europe, Scandinavia, and Poland. The company announced the completion of enrollment in this pivotal trial in July 2025.

Here's a snapshot of the NEAT trial enrollment status as of late 2025 reporting:

Metric	Value	Context
Total Participants Enrolled	105	Total participants in the Phase 3 NEAT clinical trial.
Primary Analysis Population (6-9 yrs)	83	Participants aged six to nine years old in the primary analysis group.
Older Participants (10+ yrs)	22	Participants aged 10 years and older.
Transitioned to OLE Study	24	Participants transitioned to the NEAT open label extension study (NCT06664853/IEDAT-04-2022) to date.

For the second indication, Duchenne muscular dystrophy (DMD), Quince Therapeutics, Inc. (QNCX) plans to utilize capital-efficient study approaches, which explicitly include potential investigator-initiated trials (IITs) to advance evaluation. The company reported General and Administrative (G&A) expenses of $3.3 million for the third quarter ended September 30, 2025, which includes commercial planning and new product planning costs.

Proactive investor relations via conferences and corporate updates (e.g., December 2025 events)

Quince Therapeutics, Inc. (QNCX) management has been highly visible, especially heading into the Q1 2026 topline readout expectation. The company hosted a virtual Investor Day on October 2, 2025. Furthermore, senior management participated in three major investor events in December 2025 to provide updates and discuss the pipeline ahead of the catalyst.

The December 2025 Investor Engagement Schedule:

• Piper Sandler 37th Annual Healthcare Conference: December 3, 2025.
• Oppenheimer Movers in Rare Disease Summit: December 11, 2025.
• Lunch with LifeSci: December 16, 2025.

As of November 25, 2025, the stock (QNCX) was trading at $2.67. The company reported its Q3 2025 financial results on November 12, 2025. As of September 30, 2025, cash, cash equivalents, and short-term investments stood at $26.3 million, with an expected runway through Q2 2026.

Strategic engagement with payers to secure favorable reimbursement coverage

While specific reimbursement coverage statistics aren't public, Quince Therapeutics, Inc. (QNCX) has taken concrete steps to solidify its commercial path, which directly impacts payer relationships. The company entered into a strategic relationship with Option Care Health to support the commercial launch of eDSP in the U.S.. This partnership details commercial development planning. The company expects to submit applications for approval in the U.S. and Europe in the second half of 2026, assuming positive NEAT trial results.

Key commercial planning milestones reported as of August 11, 2025, include:

• Secured financing extending runway past Q2 2026.
• Entered strategic relationship with Option Care Health.
• Reported Q2 2025 G&A expenses of $3.3 million, covering commercial planning costs.

The company's focus is on the attractive commercial opportunity for eDSP in A-T.

Quince Therapeutics, Inc. (QNCX) - Canvas Business Model: Channels

You're looking at how Quince Therapeutics, Inc. (QNCX) plans to get its specialized therapy, eDSP, from the lab bench to the patient, and how it communicates its progress. For a late-stage biotech focused on rare diseases like Ataxia-Telangiectasia (A-T), the channels are critical for both clinical execution and investor confidence.

Specialized Option Care Health Infusion Network for Drug Delivery

Quince Therapeutics, Inc. (QNCX) has locked in a key distribution and administration channel for its lead asset, encapsulated dexamethasone sodium phosphate (eDSP), in the U.S. This is a strategic relationship with Option Care Health, Inc. (OPCH), which is the nation's largest independent provider of home and ambulatory infusion services. This setup is designed to streamline the commercial launch, assuming positive study results and regulatory approval.

The scale of this channel is significant for patient access:

• The network includes more than 90 full-service pharmacies nationwide.
• It features over 180-plus ambulatory infusion suites across the U.S.
• This single provider approach replaces contracting with multiple individual academic centers of excellence for administration.

Here's a quick look at the partnership's scope for eDSP administration:

Service Component	Capacity/Scope as of Late 2025
Full-Service Pharmacies	More than 90
Ambulatory Infusion Suites	Over 180-plus
Logistics Support	Includes third-party logistics (3PL) and inventory distribution management

This single-provider strategy helps standardize the patient journey for eDSP administration, which is defintely important for a therapy targeting an ultra-rare condition.

International Network of Clinical Trial Sites for Drug Development

The development channel relies heavily on an international, multi-center approach to gather robust data for regulatory review. The pivotal Phase 3 NEAT clinical trial, which is being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA), is the primary example here.

The trial enrollment is complete, providing a concrete number for the clinical channel's output:

• Total participants enrolled in the NEAT trial: 105.
• Primary analysis population (ages six to nine): 83 participants.
• Older participants (aged 10 years and older): 22 participants.

The company also noted plans to initiate a Duchenne muscular dystrophy (DMD) Phase 2 study in 2026, which will require establishing a new set of capital-efficient study sites.

Direct Regulatory Submissions to the FDA and EMA

Quince Therapeutics, Inc. (QNCX) is channeling its clinical data directly to major regulatory bodies. The company has secured specific designations that streamline this process, which is a key de-risking channel for investors.

The planned submission timeline, contingent on positive Phase 3 NEAT results, is as follows:

Regulatory Body	Planned Submission Type	Target Submission Window
U.S. Food and Drug Administration (FDA)	New Drug Application (NDA)	Second half of 2026
European Medicines Agency (EMA)	Marketing Authorization Application (MAA)	2026

The FDA has granted the eDSP System Fast Track designation for A-T treatment. Furthermore, the Phase 3 NEAT trial is being conducted under an SPA agreement with the FDA, which locks in the trial design with the agency beforehand.

Investor Relations Platforms for Communication with Shareholders

The communication channel keeps the financial community informed, especially as the company approaches the Q1 2026 topline data readout. Quince Therapeutics, Inc. (QNCX) management actively uses investor events to convey its progress and financial standing.

Here are the scheduled engagement points from late 2025:

• Piper Sandler 37th Annual Healthcare Conference: December 3, 2025 (Fireside Chat).
• Oppenheimer Movers in Rare Disease Summit: December 11, 2025 (Panel).
• Virtual Lunch with LifeSci Featuring Quince Therapeutics: December 16, 2025 (Fireside Chat).

The financial health reported through these channels as of Q3 2025 provides context for their operational runway. As of September 30, 2025, the company reported cash, cash equivalents, and short-term investments of $26.3 million. This was expected to provide runway through Phase 3 topline results into the second quarter of 2026. The stock (QNCX) was trading at $2.67 as of November 25, 2025.

Finance: draft 13-week cash view by Friday.

Quince Therapeutics, Inc. (QNCX) - Canvas Business Model: Customer Segments

You're looking at the core groups Quince Therapeutics, Inc. (QNCX) needs to engage to bring eDSP to market for Ataxia-Telangiectasia (A-T). This is a classic rare disease model, meaning the patient pool is small but the unmet need is huge, which influences every other segment.

Patients with Ataxia-Telangiectasia (A-T), particularly the 6-9 year-old cohort

The primary focus is on patients with A-T, a severe genetic disorder. The condition typically manifests before the age of five years old. The median lifespan for these patients is only 25 to 30 years, with mortality often due to infections and malignancy. There are currently no approved therapeutic treatments in any global market for A-T, which is a key driver for their Fast Track designation. Quince Therapeutics is building its pivotal Phase 3 NEAT trial around the 6-9 year-old group, as earlier data showed success in this cohort.

Here's the quick math on the patient base:

Geographic Area	Estimated Diagnosed A-T Patients	Notes
U.S.	Approximately 4,600	Based on IQVIA Medical Claims (Dx), PharmetricsPlus (P+), and IQVIA Analytics data.
U.K. and EU4 Countries	Approximately 5,000	Quince Therapeutics estimate.

The NEAT trial enrollment numbers show direct engagement with this segment:

• Target enrollment for the 6-9 year-old primary analysis population was 86 patients.
• As of July 2025, 105 total participants were enrolled in the NEAT trial.
• Of those 105, 83 participants were in the 6-9 year-old primary analysis population.
• All enrolled NEAT participants who completed treatment elected to transition to the open-label extension study.

If onboarding takes 14+ days, churn risk rises.

Rare disease specialists and pediatric neurologists

These are the physicians who diagnose A-T and manage the patients. They are critical for trial recruitment and, post-approval, for prescribing eDSP. Quince Therapeutics has actively engaged this community to validate their endpoints and natural history understanding. For instance, they presented data on patient-reported walking capacity at the 54th Child Neurology Society (CNS) Annual Meeting in October 2025. This group needs to trust the clinical data, especially since the drug candidate, eDSP, is a novel encapsulation of dexamethasone sodium phosphate (DSP), which is known for toxicity like adrenal suppression when administered conventionally.

Key specialists include those who attended or follow the scientific meetings where Quince presented, such as:

• Attendees of the 54th Child Neurology Society (CNS) Annual Meeting (October 2025).
• Participants in the 2024 International Congress for Ataxia Research (ICAR).
• Clinicians familiar with the International Cooperative Ataxia Rating Scale (ICARS) and Rescored modified ICARS (RmICARS).

Healthcare payers and government reimbursement agencies (e.g., CMS)

Payers are the gatekeepers to access and are crucial for establishing the drug's value proposition, particularly given the high cost associated with developing and manufacturing a novel drug/device combination like the AIDE technology. Since A-T has no approved therapies, the value proposition centers on reducing the significant morbidity associated with the disease, including infections and malignancies, and avoiding the known long-term adverse effects of standard corticosteroids.

The path to securing reimbursement is tied directly to regulatory milestones:

• Planned New Drug Application (NDA) submission to the FDA in the second half of 2026, assuming positive results.
• Planned Marketing Authorization Application (MAA) submission to the EMA in the second half of 2026.
• Quince has FDA Fast Track designation, which can expedite review, a point of leverage with payers.

To prepare for commercialization, Quince Therapeutics entered into a strategic relationship with Option Care Health in Q2 2025 to support the U.S. commercial launch. This signals a clear focus on establishing a specialty pharmacy/infusion network necessary for complex rare disease treatments.

Institutional and retail biotech investors

This segment provides the capital necessary to fund the late-stage development and potential commercialization. As of late 2025, Quince Therapeutics is firmly in the pre-revenue, clinical-stage biotech profile, meaning investor interest is driven by catalysts and runway.

Financial metrics relevant to this segment as of Q3 2025 reporting (November 2025):

Metric	Value (as of late 2025)	Reporting Period/Date
Market Capitalization	$196.00M	November 24, 2025
Institutions Ownership	23.1%	November 24, 2025
Insiders Ownership	11.12%	November 24, 2025
Cash, Cash Equivalents, and Short-Term Investments	$26.3 million	September 30, 2025
Net Cash Used in Operating Activities	$30.9 million	Nine months ended September 30, 2025
Reported EPS	-$0.25	Q3 2025
Forecasted EPS Growth	From ($1.21) to ($0.79) per share next year	Post-Q3 2025

The runway is a major focus; the company expects its existing cash to cover operations through the Phase 3 NEAT topline results into the second quarter of 2026. If warrants related to recent financing are exercised, the runway extends into the second half of 2026. Retail investors are tracking the stock price, which traded at $2.67 on November 25, 2025, ahead of key investor events in December 2025.

Quince Therapeutics, Inc. (QNCX) - Canvas Business Model: Cost Structure

You're looking at the core expenses driving Quince Therapeutics, Inc. (QNCX) right now, which are heavily weighted toward advancing its lead asset, eDSP, through the pivotal Phase 3 NEAT trial. These costs dictate the cash runway and financing needs, so keeping a close eye on them is defintely key.

The primary cost drivers are clinical trial execution, general overhead, and managing existing debt obligations. Here's the quick math on the major outflows as of late 2025.

Clinical Development and Research Expenses

Research and Development (R&D) expenses are the largest variable cost, directly tied to the Phase 3 NEAT trial activities for eDSP. These costs include site management, patient monitoring, and the necessary related manufacturing for the drug/device system.

• R&D expenses for the first quarter of 2025 (Q1 2025) totaled $8.15 million.
• R&D expenses for the second quarter of 2025 (Q2 2025) were $6.6 million.
• R&D expenses for the third quarter of 2025 (Q3 2025) were $8.1 million.

The manufacturing and supply chain costs for the eDSP drug/device system are explicitly included within these R&D figures, as they relate to ongoing Phase 3 NEAT clinical trial activities.

Operational Overhead and Cash Burn

General and Administrative (G&A) costs represent the fixed overhead supporting the business outside of direct research. These expenses mainly cover personnel, stock-based compensation, and commercial planning efforts ahead of potential launch.

Expense Category	Period Ending March 31, 2025 (Q1 2025)	Period Ending September 30, 2025 (Q3 2025)
General and Administrative (G&A)	$4.79 million	$3.3 million
Net Cash Used in Operating Activities	$9.6 million (Q1 2025)	$30.9 million (9M 2025)

The significant net cash used in operating activities for the first nine months of 2025 reached $30.9 million. This burn was primarily due to the net loss of $44.5 million for the same nine-month period, adjusted for non-cash items.

Debt and Financing Obligations

Quince Therapeutics, Inc. carries debt related to its financing activities, which impacts future cash flow planning. As of June 2025, the company reported total debt of $17.0 million.

The European Investment Bank (EIB) credit facility is a key obligation. In September 2025, an amendment was made that directly impacts near-term liquidity requirements:

• Required minimum cash balance for January 1, 2026, to March 31, 2026, was reduced to €5.0 million from €14,650,000.
• 1% of the overall 9% Deferred Interest Rate on Tranche A and Tranche B of the facility is set to convert into a Fixed Rate, payable on March 31, 2026.

While the specific $12 million tranche due in 2026 mentioned in the outline wasn't explicitly detailed in the latest filings, the EIB facility structure and the June 2025 total debt of $17.0 million represent the current debt profile impacting the cost structure.

Finance: draft 13-week cash view by Friday.

Quince Therapeutics, Inc. (QNCX) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Quince Therapeutics, Inc. (QNCX) as of late 2025, and honestly, it's a classic pre-commercial biotech picture: zero sales today, but the value is all tied up in future catalysts. The current financial reality is that Quince Therapeutics, Inc. is operating on capital raised through equity, funding the final push for its lead asset, eDSP.

The core of the current revenue structure is financing, not product sales. For the trailing twelve months ending June 30, 2025, Quince Therapeutics, Inc. reported product revenue of exactly $0.00. Furthermore, analysts forecast the revenue for the full fiscal year 2025 to be $0. This is the expected state for a company focused on late-stage clinical development.

Here's a breakdown of the key financial components that constitute Quince Therapeutics, Inc.'s current and near-term revenue streams:

Revenue Stream Component	Real-Life Financial Data / Status (Late 2025)	Notes
FY 2025 Product Revenue Forecast	$0.00	Reflects pre-commercial status; TTM revenue ending June 30, 2025, was $0.00.
Equity Financing Proceeds (2025)	Upfront proceeds of $11.5 million; potential total up to $22 million	June 2025 private placement with an additional potential $10.4 million from warrant exercise.
Potential Future Product Sales (eDSP)	NDA submission planned for H2 2026 (assuming positive results)	This sets the earliest potential for commercial product revenue post-regulatory approval.
Potential Priority Review Voucher (PRV) Sale	Estimated value range of $80 million to $120 million	Market context shows PRV prices spiked to $150 million in early 2025, but this specific range is the expected potential for Quince Therapeutics, Inc.
Future Milestone Payments	Potential, amounts not specified	Contingent on potential licensing or commercial partnerships for eDSP or pipeline expansion.

You can see the financing was critical; the upfront cash from the June 2025 placement, approximately $11.5 million, plus the potential from warrant exercises up to $10.4 million, was secured to bridge operations until the Phase 3 NEAT trial topline results, expected in the first quarter of 2026.

The most significant non-dilutive, near-term value driver is the potential sale of a Priority Review Voucher (PRV). Since eDSP is for a rare pediatric disease, Quince Therapeutics, Inc. is eligible for one upon approval. While the FDA FY 2025 fee for using a voucher was set at $2,482,446, the market value of these assets is much higher, which is why the potential sale is estimated in the $80 million to $120 million range you mentioned.

Beyond the immediate financing and the PRV, the long-term revenue potential hinges on the eDSP program's success. The plan is to file the New Drug Application (NDA) in the second half of 2026, assuming positive data.

The remaining potential revenue stream involves strategic deals. Quince Therapeutics, Inc. intends to use proceeds to fund pipeline expansion into indications like Duchenne muscular dystrophy.

• Future revenue is contingent on achieving the primary efficacy endpoint in the Phase 3 NEAT trial.
• Topline results are anticipated in the first quarter of 2026.
• The company is actively planning for potential future milestone payments tied to licensing or commercialization agreements.
• The cash runway, as of September 30, 2025, was projected to last into the second quarter of 2026 based on existing cash of $26.3 million, extending into the second half of 2026 if warrants are exercised.